Skip to main content
Keegan Christensen on Muck Rack

Keegan Christensen

As seen in: BioRxiv

Get in touch with Keegan

Contact Keegan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Targeting CXCR4 with [212Pb/203Pb]-Pentixather Significantly Increases Overall Survival in Small Cell Lung Cancer

|
By Keegan Christensen, Melissa A. Fath, Jordan T. Ewald, Claudia Robles-Planells
| BioRxiv
Abstract Introduction: Small cell lung cancer (SCLC) has a 7% 5-year overall survival. C-X-C chemokine receptor 4 (CXCR4), an attractive target for theranostic agents, is highly expressed in SCLCs, and can be targeted with pentixather using the theranostic pair 212Pb/203Pb. The hypothesis that [212Pb/203Pb]-pentixather can be used safely and effectively for imaging and therapy in SCLC in xenograft models was tested.
Open in Who Shared Issue with article?

Missense mutations in Myc Box I influence MYC cellular localization, mRNA partitioning and turnover to promote leukemogenesis

|
By Nancy Arthur, Keegan Christensen, Marianna B. Ruzinova, Kathleen Mannino
| BioRxiv
Abstract Somatic missense mutations in the phosphodegron domain of the MYC gene (MYC Box I) are detected in the dominant clones of a subset of acute myeloid leukemia (AML) patients, but the mechanisms by which they contribute to AML are unknown. To unveil unique proprieties of MBI MYC mutant proteins, we systematically compared the cellular and molecular consequences of expressing similar oncogenic levels of wild type and MBI mutant MYC.
Open in Who Shared Issue with article?

Immunosuppression and Outcomes in Acute Myeloid Leukemia

|
By Christopher Miller, Keegan Christensen, Francesca Ferraro, Margareth O'Laughlin
| BioRxiv
Immunosuppression and Outcomes in Acute Myeloid Leukemia Francesca Ferraro, Christopher Miller, Keegan Christensen, Nichole M.
Open in Who Shared Issue with article?
See all 3 articles